NCT07496736

Brief Summary

The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza in a hospital setting.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P25-P50 for phase_3

Timeline
22mo left

Started Dec 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress20%
Dec 2025Mar 2028

Study Start

First participant enrolled

December 1, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 22, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 27, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2028

Last Updated

April 30, 2026

Status Verified

April 1, 2026

Enrollment Period

2.3 years

First QC Date

March 22, 2026

Last Update Submit

April 26, 2026

Conditions

Influenza

Outcome Measures

Primary Outcomes (1)

  • frequency of influenza

    10 days after completing prophylaxis

Study Arms (2)

oseltamivir 5 days

ACTIVE COMPARATOR

post-exposure influenza prophylaxis with oseltamivir for 5 days

Drug: Oseltamivir

oseltamivir 10 days

ACTIVE COMPARATOR

post-exposure influenza prophylaxis with oseltamivir for 10 days

Drug: Oseltamivir

Interventions

OseltamivirDRUG

oseltamivir 5 days

oseltamivir 5 days

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older
  • exposure to influenza during hospitalization
  • risk factors for influenza complications
  • consent for participation obtained

You may not qualify if:

  • younger than 18 years
  • hematological malignancy
  • hospitalized in intensive care unit
  • refusal to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Centre Ljubljana

Ljubljana, 1000, Slovenia

Location

MeSH Terms

Conditions

Influenza, Human

Interventions

Oseltamivir

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsOrthomyxoviridae InfectionsRNA Virus InfectionsVirus DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

AcetamidesAmidesOrganic ChemicalsCyclohexenesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbons

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD, assoc prof

Study Record Dates

First Submitted

March 22, 2026

First Posted

March 27, 2026

Study Start

December 1, 2025

Primary Completion (Estimated)

March 31, 2028

Study Completion (Estimated)

March 31, 2028

Last Updated

April 30, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

The anonymous data generated or analysed during the trial will be available from the corresponding author upon reasonable request.

Time Frame
As expected from May 01, 2026 to May 31 2028
Access Criteria
The anonymous data generated or analysed during the trial will be available from the corresponding author upon reasonable request after the study results are published.

Locations

SL(1)